Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sarepta sells priority review voucher to Gilead for $125mm

Executive Summary

Sarepta Therapeutics Inc. sold its rare pediatric disease priority review voucher (PRV) to Gilead Sciences Inc. for $125mm. Sarepta was granted the PRV when Exondys51 was approved by the FDA for patients with Duchenne muscular dystrophy amenable to exon skipping, and will now use the cash from the sale to support development of additional exon skipping candidates and enhancement of the company's antisense platform.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies

UsernamePublicRestriction

Register